Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Luminex Receives FDA Clearance For An Update To The XTAG(R) Respiratory Viral Panel Package Insert
Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared labeling updates for the company"s xTAG® Respiratory Viral Panel (RVP) to include data about the performance of the test in humans infected with the pandemic strain of influenza A, 2009 influenza A/H1N1, which is sometimes referred to as "swine flu." The test"s labeling has been updated to include information from two new studies that demonstrate that xTAG RVP can be an effective aid in the detection of 2009 Influenza A/HIN1, but cannot identify the hemagglutinin gene of the 2009 Influenza A/H1N1 in clinical specimens.

Brain Functions That Can Prevent Relapse Improve After A Year Of Methamphetamine Abstinence
In a study published online by the Journal of Substance Abuse Treatment, UC Davis researchers report that it takes at least a year for former methamphetamine users to regain impulse control. The results tell recovering substance abusers, their families and drug-treatment specialists that it can take an extended period of time for the brain functions critical to recovery to improve.
News of the day
PanGenetics Receives Approval For Clinical Evaluation Of Anti-NGF Antibody In Patients With Chronic Pain
PanGenetics B.V. announced that the Competent Authority of the Netherlands has approved the Clinical Trials Application for a first-in-man study with antibody PG110. This humanized antibody is a member of the class of Nerve Growth Factor (NGF) inhibitors which represent a promising novel approach in the treatment of chronic pain. PG110 will be evaluated in patients suffering from pain caused by osteoarthritis (OA). The clinical trial is designed as a double blind, placebo controlled study and will be conducted in a single site in Utrecht, the Netherlands, in collaboration with Kendle International.
Endocrinology

Brain-Scanning Process That Holds Promise For Epilepsy Treatments Developed By University Of Minnesota Researcher

University of Minnesota McKnight professor and Director of Center for Neuroengineering Bin He has developed a new technique that has led to preliminary successes in noninvasive imaging of seizure foci. He"s technique promises to play an important role in the treatment of epileptic seizures. Click here to view a video explaining the procedure. He"s research, called Functional Neuroimaging, has completed its first round of testing in epilepsy data collected at the Mayo Clinic. He"s medical device images the brain while epilepsy patients have a seizure and then allows surgeons to identify the network where the seizure is caused. Approximately one-third of people who suffer from epileptic seizures cannot be treated by medication, and this process could lead to further advancements in surgical treatment. He"s research is funded by the National Institutes of Health and the National Science Foundation. Patty Mattern University of Minnesota


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009